Abstract
Multiple sclerosis (MS) is one of the commonest causes of neurological disability in young adults. Currently more than 1.2million people are affected worldwide by this disease, and the relapsing-remitting form of MS exhibits a gender disequilibrium of 3:1 for female affliction. There are several lines of evidence that multiple sclerosis is an autoimmune disease, which may be modified by genetic factors (see review in Compston et al. 2005). Following the initial formulation of the disease concept by the great French neurologist Jean-Martin Charcot in the 1860s, virtually hundreds of (bizarre) remedies were proposed over the subsequent 100 years. The approval in 1993 of interferon- q -1b as the first immunomodulatory treatment for relapsing-type MS represents a milestone in MS therapeutics. In view of the limited efficacy of these agents, the search must continue for better, more effective therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bielekova B, Richert N, Howard T, et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity inmultiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101:8705–8708
Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103:5941–5946
Coles AJ, Wing MG, Molyneux P, et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304
Compston A, Confavreux C, Lassmann H, et al. (2005) McAlpine’s multiple sclerosis. Churchill Livingstone, London
Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272
Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26:485–495
Franklin RJM (2002) Why does remyelination fail in multiple sclerosis? Nature Rev Neurosci 3:705–714
Hafler DA (2004) Multiple sclerosis. J Clin Invest 113:788–794
Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP (2006) Immunopathogenesis and immunotherapy of multiple sclerosis. Nature Clin Practice Neurol 2:201–211
Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis — Principles, problems and perspectives. Brain 120:865–916
Hohlfeld R, Wekerle H (2005) Drug insight: using monoclonal antibodies to treatmultiple sclerosis. Nature Clin Pract Neurol 1:34–44
Kawakami N, Nagerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flugel A (2005) Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J Exp Med 201:1805–1814
Luhder F, Huang Y, Dennehy KM, et al. (2003) Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197:955–966
Miller DH, Khan OA, Sheremata WA, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15–23
Moreau T, et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion inmultiple sclerosis. Lancet 344:298–301
Polman CH, O’Connor PW, Havrdova E, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910
Probert L, Eugster HP, Akassoglou K, et al. (2000) TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 123:2005–2019
Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8:1275
Rizvi SA, Bashir K (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63(Suppl 6):S47–S54
Rudick RA, Stuart WH, Calabresi PA, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923
Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885–1888
Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683–747
Stuve O, Cepok S, Elias B, et al. (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 62:1620–1623
The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465
Van Oosten BW, Barkhof F, Truyen L, et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531–1534
Weishaupt A, Gold R, Gaupp S, Giegerich G, Hartung HP, Toyka KV (1997) Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. Proc Natl Acad Sci U S A 94:1338–1343
Wekerle H, Linington C, Lassmann H, Meyermann R (1986) Cellular immune reactivity within the CNS. Trends Neurosci 9:271–277
Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 356:63–66
Yousry TA, Major EO, Ryschkewitsch C, et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924–933
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gold, R., Hohlfeld, R. (2007). Multiple Sclerosis: New Immunobiologics. In: Boehncke, WH., Radeke, H.H. (eds) Biologics in General Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29018-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-540-29018-6_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-29017-9
Online ISBN: 978-3-540-29018-6
eBook Packages: MedicineMedicine (R0)